hold-BUZZ-Mithra: Rises as drug Estelle wins FDA marketing exclusivity

Mithra Pharmaceuticals SA

27/05/2021 09:00

** Shares in Mithra Pharmaceuticals  MITRA.BR  rise as much
as 3% after its contraceptive drug Estelle, developed together
with Australia's Mayne Pharma  MYX.AX , obtains FDA marketing
exclusivity for five years  urn:newsml:reuters.com:*:nFWN2ND0X4
    ** KBC Securities says market exclusivity adds another layer
of protection against possible genericized versions of the drug
    ** "We expect the key protection to come from the patents
surrounding Estelle and its synthesis pathways until 2032," the
broker adds
    ** Mayne Pharma was up 2.8% at market close in Australia


 ((michal.aleksandrowicz@tr.com; piotr.lipinski@tr.com))